Boston, MANCT06137144Now EnrollingIRB Ready

Lymphoma Clinical Trial in Boston, MA

Access cutting-edge lymphoma treatment through this phase 1/2 clinical trial at a research site in Boston. Study-provided care at no cost to qualified participants.

Sponsored by AstraZeneca

Quick Self-Assessment

See if you qualify for this Boston location

Preparing your pre-screening questions…

Expert Care in Boston

Access lymphoma specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related lymphoma treatment provided free

Apply for This Boston Location

Check if you qualify for this lymphoma clinical trial in Boston, MA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Boston

    Convenient for MA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Boston site if eligible
  4. 4Begin participation

About This Lymphoma Study in Boston

This study is designed to evaluate the safety, tolerability, PK and preliminary efficacy following oral administration of AZD3470 as a monotherapy, and in combination with other anticancer agents in participants with haematologic malignancies.

Sponsor: AstraZeneca

Who Can Participate

Inclusion Criteria

Core Inclusion criteria:
Adequate adult (ECOG) or adolescent (Karnofsy or Lanksy) Performance Score assessments
Adequate organ and bone marrow function. Module 1 Cohort 1:
Part A (dose escalation): aged ≥ 18 years at the time of signing the informed consent.
Part B (optimization): aged ≥ 12 years of age. Adolescent participants must weigh ≥ 40 kg.
Histologically confirmed diagnosis of cHL based on WHO criteria
Previous treatment with at least 2 prior lines of therapy for the treatment of cHL (including at least 2 cycles of BV and anti-PD1) and have documented r/r active disease requiring treatment.
Participants must provide FFPE baseline tumour tissue.
At least 1 radiographically measurable, and/or FDG-avid lymphoma lesion ( \>1.5 cm for nodal lesion and \>1 cm for extranodal lesion). Module 1 Cohort 2:
Participants must be at least 50 years of age or older at study entry.
Histologically confirmed diagnosis of cHL based on WHO criteria
Ann Arbor stages III or IV.
Participant must have previously received at least 4 cycles of SoC combination therapy with A-AVD, N-AVD, AVD, or ABVD (based on regional SOC, per investigator) as finite first-line induction therapy, and achieved at least a PR post-induction therapy.
Participants must provide FFPE baseline tumour tissue. Module 1 Cohort 3:
Participants must be aged ≥ 18 years at the time of signing the informed consent.
Histologically confirmed diagnosis of PTCL NOS, systemic ALCL, or AITL based on WHO criteria.
Participants must have received at least 1 prior line of therapy for the treatment of PTCL and have exhausted all available therapies with demonstrated clinical benefit. Participants with ALCL must have received prior BV treatment.
Participants must provide FFPE baseline tumour tissue a. Ability to provide an on-treatment biopsy (if the tumour is suitable for biopsy).
At least 1 radiographically measurable, and/or FDG-avid lymphoma lesions (\> 1.5 cm for nodal lesion and \>1 cm for extranodal lesion). Module 2 Cohort 1:
Participants must be aged ≥ 18 years at the time of signing the informed consent.
Histologically confirmed diagnosis of cHL based on WHO criteria
At least 1 radiographically measurable, and/or FDG-avid lymphoma lesions (\> 1.5 cm for nodal lesion and \>1 cm for extranodal lesion).
Participant must have received at least 1 prior line of therapy for the treatment of cHL and have documented r/r active disease requiring treatment.
Participants must provide FFPE baseline tumour tissue.

Exclusion Criteria

Core Exclusion criteria:
Any significant laboratory finding or any severe and uncontrolled medical condition.
Active CNS involvement by lymphoma, leptomeningeal disease, or spinal cord compression.
Serologic active HBV or HCV infection.
Known to have tested positive for HIV.
Active gastrointestinal disease or other condition that will interfere with oral therapy.
Any of the following ECG cardiac criteria: Mean resting QTcF \> 470 msec, clinically important abnormalities in rhythm, conduction or morphology, and/or any factors that increase the risk of QTc prolongation or risk of arrhythmic events.
Undergone any of the following procedures within 6 months prior to first dose:
Coronary artery bypass graft,
Percutaneous coronary intervention or heart valve replacement or repairment,
Vascular stent implantation (venous stent is eligible),
Acute coronary syndrome / myocardial infarction,
Unstable or poorly controlled angina pectoris,
Ventricular arrhythmias requiring continuous therapy,
Uncontrolled atrial fibrillation,
Haemorrhagic or thrombotic stroke (including transient ischaemic attacks) or any other CNS bleeding.
Acute venous or atrial thromboembolic event (unless considered stable or adequately treated with at least 3months of therapeutic anticoagulation).
Severe valvular heart disease.
Congestive heart failure Grade II to Grade IV.
Prior or current cardiomyopathy.
Uncontrolled hypertension.
History of significant haemoptysis or haemorrhage within4 weeks of the first dose of study treatment.
Unresolved toxicities of Grade \> 1 from prior anti cancer therapy (excluding peripheral neuropathy, vitiligo, alopecia and endocrine disorders that are controlled with replacement hormone therapy, and asymptomatic laboratory abnormalities), unless immune-mediated.
History of another primary malignancy.
Received the following anticancer therapies: anti-lymphoma therapy (within 21 days), radiation therapy(within 28 days), allo-HSCT (within 180 days), auto-HSCT/cellular therapy (within 60 days), or MAT2A or PRMT5 inhibitor
Requires ongoing immunosuppressive therapy, including systemic corticosteroids. Module 2 Cohort 1:
History of confirmed ILD, drug-induced ILD, radiation pneumonitis requiring steroid treatment or any evidence of clinically active ILD or pneumonitis.
≥Grade 3 immune-mediated AE while receiving prior checkpoint inhibitor immunotherapy, or any unresolved ≥Grade 2 immune-mediated AE.
History of immune-mediated myocarditis or pericarditis.
Experienced a toxicity that led to permanent discontinuation of prior immunotherapy.
Active or prior documented pathologically confirmed autoimmune or inflammatory disorders
Refractory to prior checkpoint inhibitor therapy (within 12 weeks of last dose)
Eligible for allogeneic or autologous stem cell transplant.
Received an allogeneic HSCT within 5 years of the first dose of study treatment; must not have active Graft-versus-host disease.
Participants with a known hypersensitivity to pembrolizumab or any of the excipients of the product.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Boston?

Yes, this clinical trial (NCT06137144) has an active research site in Boston, MA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Lymphoma Treatment Options in Boston, MA

If you're searching for lymphoma treatment options in Boston, MA, this clinical trial (NCT06137144) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Boston research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced lymphoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all lymphoma clinical trials near you to find additional studies recruiting in your area.

More Lymphoma Trials in Boston, MA

See all lymphoma clinical trials recruiting in Boston — not just this study.

Browse Lymphoma Trials in Boston →

Browse More Trials by Condition

Lymphoma TrialsChronic Lymphocytic Leukemia TrialsDiffuse Large B-Cell Lymphoma TrialsFollicular Lymphoma TrialsMantle Cell Lymphoma TrialsWaldenstrom Macroglobulinemia TrialsPulmonary Hypertension TrialsPeripheral T-Cell Lymphoma TrialsAll Conditions →

Ready to Join in Boston?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Boston, MA